Back to top
more

Bruker (BRKR)

(Real Time Quote from BATS)

$82.25 USD

82.25
714,690

-0.21 (-0.26%)

Updated Apr 24, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (35 out of 252)

Industry: Instruments - Scientific

Better trading starts here.

Zacks News

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Bruker (BRKR) Expands Materials Science Research via New Deal

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.

Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University

Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.

Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%

Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Bruker (BRKR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why Investors Should Buy Bruker (BRKR) Stock Now

The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.

Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG

Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.

Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter

Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.

Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities

Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.

Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems

Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.

Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal

Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.

Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up

Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates

Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q2 Earnings and Revenues Top Estimates

Waters (WAT) delivered earnings and revenue surprises of 8.11% and 0.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.

Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023

Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.

Bruker (BRKR) Launches the SciY Platform of Software Solutions

Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.